0001004878-17-000246.txt : 20171201
0001004878-17-000246.hdr.sgml : 20171201
20171201123013
ACCESSION NUMBER: 0001004878-17-000246
CONFORMED SUBMISSION TYPE: 8-K
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20171128
ITEM INFORMATION: Material Modifications to Rights of Security Holders
FILED AS OF DATE: 20171201
DATE AS OF CHANGE: 20171201
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: CEL SCI CORP
CENTRAL INDEX KEY: 0000725363
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 840916344
STATE OF INCORPORATION: CO
FISCAL YEAR END: 0930
FILING VALUES:
FORM TYPE: 8-K
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-11889
FILM NUMBER: 171233358
BUSINESS ADDRESS:
STREET 1: 8229 BOONE BLVD .
STREET 2: SUITE 802
CITY: VIENNA
STATE: VA
ZIP: 22182
BUSINESS PHONE: 7035069460
MAIL ADDRESS:
STREET 1: 8229 BOONE BLVD.
STREET 2: SUITE 802
CITY: VIENNA
STATE: VA
ZIP: 22182
FORMER COMPANY:
FORMER CONFORMED NAME: INTERLEUKIN 2 INC
DATE OF NAME CHANGE: 19880317
8-K
1
form8k303ddeewar11-17.txt
FORM 8-K ITEM 3.03
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (date of earliest event reported): November 28, 2017
CEL-SCI CORPORATION
--------------------------------------
(Exact name of Registrant as specified in its charter)
Colorado 001-11889 84-0916344
-------------------- ------------------ -----------------
(State or other jurisdiction (Commission File No.) (IRS Employer
of incorporation) Identification No.)
8229 Boone Boulevard, Suite 802
Vienna, Virginia 22182
--------------------------------------
(Address of principal executive offices, including Zip Code)
Registrant's telephone number, including area code: (703) 506-9460
N/A
--------------------------------------
(Former name or former address if changed since last report)
1
Item 3.03. Material Modification to Rights of Security Holders.
On November 28, 2017 the Company extended the expiration date of its Series
DD and Series EE warrants to March 1, 2018. The Series DD and Series EE warrants
were issued as part of a financing on December 8, 2016. As a result of the
reverse stock split approved by the Company's shareholders and adopted by the
Company's directors,
o the holders of the Series DD warrants are entitled to purchase
1,360,960 shares of the Company's common stock at an exercise price of
$4.50 per share, and
o the holders of the Series EE warrants are entitled to purchase
1,360,960 shares of the Company's common stock at an exercise price of
$4.50 per share
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: December 1, 2017 CEL-SCI CORPORATION
By: /s/ Patricia Prichep
--------------------------------
Patricia Prichep
Senior Vice President of Operations